文献速递生殖医学

对辅助生殖多周期治疗规划与延续干预原型在医护人员和患者中可接受性与可行性的定性评价

Qualitative evaluation of the acceptability and feasibility among healthcare professionals and patients of an ART multi-cycle treatment planning and continuation intervention prototype.
PubMed 文献 · Hum Reprod · 2023-01-01

该定性研究于2021年5月对13名医护人员和13名患者进行在线认知访谈,评估辅助生殖治疗规划与延续干预(TPCI)原型的可接受性与可行性。参与双方均积极评价TPCI,认为其是支持患者坚持计划治疗的可接受干预,但部分医护人员对在实际工作中使用的可行性表示担忧。

要点

  • 医护人员和患者对TPCI原型反应积极,认为其可接受且可能有效。
  • TPCI Checklist当前长度在时间压力和临床工作量下实施具挑战性。
  • 患者均为女性且主要来自患者支持团体,可能对治疗高度投入。

核心结论

  • 医护人员和患者对TPCI原型反应积极,认为其是支持患者坚持计划治疗的可接受干预,但部分人对实际使用的可行性表示担忧。

研究设计与样本

  • 2021年5月对医护人员和患者进行定性认知访谈。
  • 共13名医护人员和13名患者参与25次在线访谈。
  • 患者纳入条件为招募前8周内曾就诊启动首次或再次刺激的IVF/ICSI周期、年龄18岁及以上(女性上限42岁)且英语流利。
  • 医护人员纳入条件为受雇于生育诊所并负责进行治疗规划咨询。
  • 访谈时长40至90分钟,录音并逐字转录,采用主题分析。

主要发现

  • 主题分析使用归纳和演绎编码生成180个编码,归为22个类别并综合为9个主题。
  • 主题显示医护人员和患者对TPCI给予积极反馈,认为其是预警多周期可能需求、提供患者-诊所协作感与支持、增强治疗意图的所需、可接受且可能有效的方式。
  • 医护人员认为TPCI Checklist当前长度在时间压力和诊所工作量下实施具挑战性。
  • 参与者对TPCI Checklist和App提出改进建议,但无需对其核心组件或活动进行关键性更改。

关键数值与推荐

  • TPCI包含两个组件:供医护人员在规划咨询中使用的期望管理与推理清单(TPCI Checklist)及供患者在治疗前和治疗期间使用的多特征认知支持移动应用(TPCI App)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有患者均为女性,从社交媒体网站招募,主要与患者支持团体相关,可能对生育治疗高度投入。
  • 医护人员主要来自私立生育诊所。
  • 未来研究需要开发原型并检验TPCI在诊所中实施的可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is it possible to design an ART Treatment Planning and Continuation Intervention (TPCI) that is considered acceptable and feasible to patients and healthcare professionals (HCPs)? SUMMARY ANSWER: HCPs and patients responded positively to the TPCI prototype and perceived it as an acceptable intervention to support patients to stay engaged with planned treatment, but some concerns were raised about the feasibility of using it in practice. WHAT IS KNOWN ALREADY: People discontinue ART due to its psychological burden. Digital tools to support people undergoing ART are available but typically focus only on practical support rather than psychological support. Research about treatment continuation and multi-cycle planning indicates that cognitive factors (expectations, intentions, efficacy beliefs) should be targets of interventions designed to help patients engage with and continue treatment to meet their personal treatment plans and goals. However, it is not known whether this form of psychological support would be acceptable for HCPs and patients or feasible to implement in practice. STUDY DESIGN, SIZE, DURATION: Qualitative cognitive interviews with HCPs and patients (May 2021). Patients were eligible if they had had a consultation to start a first/repeat stimulated IVF/ICSI cycle in the 8 weeks prior to recruitment, were aged 18 or older (upper age limit of 42 years for women) and fluent in English. Eligible HCPs were those employed by a fertility clinic who were responsible for delivering treatment planning consultations to patients. PARTICIPANTS/MATERIALS, SETTING, METHODS: HCPs and patients were asked to think aloud while being exposed to and exploring the TPCI in one-to-one online cognitive interviews. The TPCI was designed to reduce treatment discontinuation via cognitive factors namely formation and maintenance of multi-cycle ART intentions and efficiency of decision-making during treatment, and continuation of treatment after an unsuccessful cycle (when recommended). To impact cognitive factors the TPCI comprised of two components: an expectation management and reasoning checklist for HCPs to use during planning consultations (TPCI Checklist) and a multi-feature cognitive support mobile application (TPCI App) for patients to use prior to and during treatment. After participants thought aloud while being exposed to the TPCI prototype (both components) they were asked open questions concerning their perceptions of the core components and activities on eight acceptability dimensions (e.g. acceptability, demand, integration). Interviews lasted between 40 and 90 min, were recorded, transcribed verbatim and analysed using thematic analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Thirteen HCPs and 13 patients participated in 25 online interviews. Thematic analysis using inductive and deductive coding generated 180 codes, grouped into 22 categories and synthesized into 9 themes. The themes showed that HCPs and patients provided positive feedback about the TPCI, perceiving it as a needed, acceptable and potentially effective way to forewarn patients of the possible need for multiple cycles, to provide patients with a sense of patient-clinic collaboration and support, and to bolster treatment intentions, all of which were perceived to contribute to reduced treatment discontinuation. HCPs perceived implementation of the TPCI Checklist to be challenging in its current length due to time pressures and clinic workload. Suggestions for enhancing the TPCI Checklist and App were provided, but none required critical changes to its core components or activities. LIMITATIONS, REASONS FOR CAUTION: All patients were women recruited from social media websites, mainly associated with patient support groups, who may be highly committed to their fertility treatment. HCPs were predominantly from private fertility clinics. WIDER IMPLICATIONS OF THE FINDINGS: The findings suggest there is demand for digital support geared towards motivational aspects of undergoing ART. The TPCI is an acceptable support tool to meet that need according to HCPs responsible for delivering planning consultations and patients undergoing fertility treatment. Future research is needed to develop the prototype and examine the feasibility of implementation of the TPCI in clinics. STUDY FUNDING/COMPETING INTEREST(S): This research was financially supported by Merck Serono Ltd, an affiliate of Merck KGaA, Darmstadt, Germany. 'Merck KGaA, Darmstadt, Germany reviewed the manuscript for medical accuracy only before journal submission. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors' J.B. reports personal fees from Merck KGaA, Darmstadt, Germany, Merck AB an affiliate of Merck KGaA, Darmstadt Germany, Theramex, Organon JJC, Ferring Pharmaceuticals A/S, research grant from Merck Serono Ltd, grants from ESHRE outside the submitted work and that she is co-developer of Fertility Quality of Life (FertiQoL) and MediEmo app. S.G. reports consultancy fees from TMRW Life Sciences and Ferring Pharmaceuticals A/S, speaker fees from Access Fertility, SONA-Pharm LLC, Meridiano Congress International and Gedeon Richter. C.H. declares no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Harrison C, Gameiro S, Boivin J, et al. Qualitative evaluation of the acceptability and feasibility among healthcare professionals and patients of an ART multi-cycle treatment planning and continuation intervention prototype. Hum Reprod. 2023. PMID: 36637254. doi:10.1093/humrep/deac272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。